Kazia is developing a drug called GDC-0084 for the treatment of Glioblastoma (GBM) and other cancers, which was licensed from US pharmaceutical group, Genentech and is currently in phase II human trials
'Tis the season for good deeds, and Boehringer Ingelheim employees are doing their part. BI is once again partnering with the Bonnie J. Addario Lung Cancer Foundation (ALCF) to bring holiday cheer directly to lung cancer patients.